Introduction and Objective: To evaluate the feasibility and effectiveness of the PACTAID application in reducing hypoglycemia during and after exercise in adults with type 1 diabetes (T1D) using the Tandem Control-IQ system.Methods: In this prospective study, adults with T1D on Control-IQ completed 20 exercise sessions with PACTAID support. Baseline and end-of-study assessments included ambulatory blood pressure, VO2 max, and laboratory testing. CGM data were analyzed between exercise and non-exercise days and from baseline through study participation.Results: Ten participants (6 males, 4 females; mean age 46.3 years; BMI 28.3±6.2 kg/m²) completed the 4-week study. CGM metrics were similar on exercise and non-exercise days (all p>0.05, Table 1). Across participants, time below range decreased significantly (p=0.04), while time in range increased and time above range decreased without significance. Hypoglycemic events were unchanged. No group-level changes were observed in HbA1c, lipid profiles, VO2 max, or ambulatory arterial stiffness, though fructosamine rose modestly (p=0.04). Individual improvements in lipid parameters and hs-CRP occurred in over half of participants.Conclusion: PACTAID use during exercise maintained glycemic stability and reduced hypoglycemia without increasing hyperglycemia, supporting the feasibility and safety of digital exercise-support tools integrated with automated insulin delivery.
R. Kaur: None. A. Banerjee: None. L.J. Plaza Enriquez: None. M. Cescon: Advisory Panel; Ended; Diatech Diabetes, Inc. K.R. Bailey: None. S. Gupta: None. Y. Kudva: Advisory Panel; Current; Tandem Diabetes Care, Inc., Vertex Pharmaceuticals Incorporated, Novo Nordisk. Research Support; Current; Insulet Corporation.
ASU-Mayo Seed Grant
Source link
Leave a Reply